Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells

References

• Crozier JA, Swaika A, Moreno-Aspitia A. Adjuvant chemotherapy in breast cancer: to use or not to use, the anthracyclines. World J Clin Oncol. 2014;5:529–538.
   PubMedGoogle Scholar
• Shukla S, Ohnuma S, Ambudkar SV. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets. 2011;12:621–630.
   PubMed Web of Science ®Google Scholar
• Rahman M, Hasan MR. Cancer metabolism and drug resistance. Metabolites. 2015;5:571–600.
   PubMed Web of Science ®Google Scholar
• Kapse-Mistry S, Govender T, Srivastava R, et al. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 2014;5:159.
   PubMed Web of Science ®Google Scholar
• Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets. 2006;6:295–311.
   PubMed Web of Science ®Google Scholar
• Liu F-S. Mechanisms of chemotherapeutic drug resistance in cancer therapy–a quick review. Taiwan J Obstet Gynecol. 2009;48:239–244.
   PubMed Web of Science ®Google Scholar
• Schmitt L, Tampe R. Structure and mechanism of ABC transporters. Curr Opin Struct Biol. 2002;12:754–760.
   PubMed Web of Science ®Google Scholar
• Kock K, Grube M, Jedlitschky G, et al. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin Pharmacokinet. 2007;46:449–470.
   PubMed Web of Science ®Google Scholar
• Glavinas H, Krajcsi P, Cserepes J, et al. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv. 2004;1:27–42.
   PubMedGoogle Scholar
• Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6:1769–1792.
   PubMed Web of Science ®Google Scholar
• Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci. 2009;30:546–556.
   PubMed Web of Science ®Google Scholar
• Tiwari AK, Sodani K, Dai C-L, et al. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 2011;12:570–594.
   PubMed Web of Science ®Google Scholar
• Wu C-P, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008;1:93–105.
   PubMedGoogle Scholar
• Cox AG. Pharmacogenomics and drug transport/efflux. In: Olson R, editor. Concepts in pharmacogenomics. Maryland (MD): American Society of Health-System Pharmacists; 2010 p. 129–154.
   Google Scholar
• Turner JG, Gump JL, Zhang C, et al. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006;108:3881–3889.
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–234.
   PubMed Web of Science ®Google Scholar
• Kuo MT. Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2009;11:99–133.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Alakhova DY, Kabanov AV. Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev. 2013;65:1763–1783.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang C-Y, Liu T, et al. Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol. 2008;14:925–930.
   PubMed Web of Science ®Google Scholar
• Tiwari AK, An X, Chen Z-S. The role of stem cell markers in multidrug resistance mediated by ABC transporters. Leuk Res. 2010;34:696–697.
   PubMed Web of Science ®Google Scholar
• Doktorova H, Hrabeta J, Khalil MA, et al. Hypoxia-induced chemoresistance in cancer cells: the role of not only HIF-1. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159:166–177.
   PubMed Web of Science ®Google Scholar
• Moitra K. Overcoming multidrug resistance in cancer stem cells. Biomed Res Int. 2015;2015:635745.
   PubMed Web of Science ®Google Scholar
• Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov. 2014;13:497–512.
   PubMed Web of Science ®Google Scholar
• Gillet J-P, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta. 2007;1775:237–262.
   PubMed Web of Science ®Google Scholar
• Bunting KD, Zhou S, Lu T, et al. Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. Blood. 2000;96:902–909.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Chumsri S, Khakpour N, et al. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer. 2010;102:815–826.
   PubMed Web of Science ®Google Scholar
• Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004;101:14228–14233.
   PubMed Web of Science ®Google Scholar
• Chen KG, Valencia JC, Gillet J-P, et al. Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res. 2009;22:740–749.
   PubMed Web of Science ®Google Scholar
• Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345–349.
   PubMed Web of Science ®Google Scholar
• Ayers D, Baron B, Hunter T. miRNA influences in NRF2 pathway interactions within cancer models. J Nucleic Acids. 2015;2015:143636.
   PubMed Web of Science ®Google Scholar
• Raaijmakers MH, Scadden DT. Evolving concepts on the microenvironmental niche for hematopoietic stem cells. Curr Opin Hematol. 2008;15:301–306.
   PubMed Web of Science ®Google Scholar
• Jaworska D, Krol W, Szliszka E. Prostate cancer stem cells: research advances. Int J Mol Sci. 2015;16:27433–27449.
   PubMed Web of Science ®Google Scholar
• Welte Y, Adjaye J, Lehrach HR, et al. Cancer stem cells in solid tumors: elusive or illusive? Cell Commun Signal. 2010;8:6.
   PubMed Web of Science ®Google Scholar
• de Grouw EP, Raaijmakers MH, Boezeman JB, et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells. Leukemia. 2006;20:750–754.
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988.
   PubMed Web of Science ®Google Scholar
• Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–5828.
   PubMed Web of Science ®Google Scholar
• Tirino V, Desiderio V, Paino F, et al. Methods for cancer stem cell detection and isolation. Methods Mol Biol. 2012;879:513–529.
   PubMedGoogle Scholar
• Tsuruo T, Hamada H, Sato S, et al. Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn J Cancer Res. 1989;80:627–631.
   PubMedGoogle Scholar
• Slater LM, Sweet P, Stupecky M, et al. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest. 1986;77:1405–1408.
   PubMed Web of Science ®Google Scholar
• Slater LM, Murray SL, Wetzel MW, et al. Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance. Cancer Chemother Pharmacol. 1986;16:50–54.
   PubMed Web of Science ®Google Scholar
• Raaijmakers MH, de Grouw EP, van der Reijden BA, et al. ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin Cancer Res. 2006;12:3452–3458.
   PubMed Web of Science ®Google Scholar
• Fletcher JI, Haber M, Henderson MJ, et al. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010;10:147–156.
   PubMed Web of Science ®Google Scholar
• Chen K, Huang Y-H, Chen J-L. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013;34:732–740.
   PubMed Web of Science ®Google Scholar
• Rabindran SK, Ross DD, Doyle LA, et al. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000;60:47–50.
   PubMed Web of Science ®Google Scholar
• van Loevezijn A, Allen JD, Schinkel AH, et al. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorg Med Chem Lett. 2001;11:29–32.
   PubMed Web of Science ®Google Scholar
• Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps J. 2005;7:E118–E133.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Tsukahara S, Ishikawa E, et al. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci. 2005;96:457–465.
   PubMed Web of Science ®Google Scholar
• Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22:7340–7358.
   PubMed Web of Science ®Google Scholar
• Katayama K, Masuyama K, Yoshioka S, et al. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother Pharmacol. 2007;60:789–797.
   PubMed Web of Science ®Google Scholar
• Limtrakul P, Chearwae W, Shukla S, et al. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem. 2007;296:85–95.
   PubMed Web of Science ®Google Scholar
• Skupien K, Kostrzewa-Nowak D, Oszmianski J, et al. In vitro antileukaemic activity of extracts from chokeberry (Aronia melanocarpa [Michx] Elliott) and mulberry (Morus alba L.) leaves against sensitive and multidrug resistant HL60 cells. Phytother Res. 2008;22:689–694.
   PubMed Web of Science ®Google Scholar
• Ludwig JA, Szakacs G, Martin SE, et al. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res. 2006;66:4808–4815.
   PubMed Web of Science ®Google Scholar
• Dai C-L, Tiwari AK, Wu C-P, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008;68:7905–7914.
   PubMed Web of Science ®Google Scholar
• Tiwari AK, Sodani K, Wang S-R, et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009;78:153–161.
   PubMed Web of Science ®Google Scholar
• Shi Z, Peng -X-X, Kim I-W, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 2007;67:11012–11020.
   PubMed Web of Science ®Google Scholar
• Sims JT, Ganguly SS, Bennett H, et al. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One. 2013;8:e55509.
   PubMed Web of Science ®Google Scholar
• Deng J, Shao J, Markowitz JS, et al. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors. Pharm Res. 2014;31:2237–2255.
   PubMed Web of Science ®Google Scholar
• Wang Y-J, Zhang Y-K, Kathawala RJ, et al. Repositioning of tyrosine kinase inhibitors as antagonists of ATP-binding cassette transporters in anticancer drug resistance. Cancers (Basel). 2014;6:1925–1952.
   PubMed Web of Science ®Google Scholar
• Kathawala RJ, Gupta P, Ashby CR Jr., et al. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015;18:1–17.
   PubMed Web of Science ®Google Scholar
• Thomas-Schoemann A, Blanchet B, Bardin C, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol. 2014;89:179–196.
   PubMed Web of Science ®Google Scholar
• Kieran MW, Kalluri R, Cho Y-J. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med. 2012;2:a006593.
   PubMed Web of Science ®Google Scholar
• Imai Y, Yoshimori M, Fukuda K, et al. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Oncol Rep. 2012;27:1703–1709.
   PubMed Web of Science ®Google Scholar
• Zinzi L, Capparelli E, Cantore M, et al. Small and innovative molecules as new strategy to revert MDR. Front Oncol. 2014;4:2.
   PubMedGoogle Scholar
• Huang F-F, Zhang L, Wu D-S, et al. PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia. PLoS One. 2014;9:e88298.
   PubMed Web of Science ®Google Scholar
• Chen Y, Bieber MM, Teng NN. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer. Mol Carcinog. 2014;53:625–634.
   PubMed Web of Science ®Google Scholar
• Xu D, Kang H, Fisher M, et al. Strategies for inhibition of MDR1 gene expression. Mol Pharmacol. 2004;66:268–275.
   PubMed Web of Science ®Google Scholar
• Friedman D, Hu Z, Kolb EA, et al. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 2002;62:3377–3381.
   PubMed Web of Science ®Google Scholar
• Wang TH, Wang HS, Ichijo H, et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem. 1998;273:4928–4936.
   PubMed Web of Science ®Google Scholar
• Kurz EU, Cole SP, Deeley RG. Identification of DNA-protein interactions in the 5ʹ flanking and 5ʹ untranslated regions of the human multidrug resistance protein (MRP1) gene: evaluation of a putative antioxidant response element/AP-1 binding site. Biochem Biophys Res Commun. 2001;285:981–990.
   PubMed Web of Science ®Google Scholar
• Kim B, Stephen SL, Hanby AM, et al. Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy. BMC Cancer. 2015;15:634.
   PubMed Web of Science ®Google Scholar
• van Vlerken LE, Duan Z, Seiden MV, et al. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 2007;67:4843–4850.
   PubMed Web of Science ®Google Scholar
• Komarov PG, Shtil AA, Buckingham LE, et al. Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function. Int J Cancer. 1996;68:245–250.
   PubMed Web of Science ®Google Scholar
• Alakhova DY, Kabanov AV. Pluronics and MDR reversal: an update. Mol Pharm. 2014;11:2566–2578.
   PubMed Web of Science ®Google Scholar
• Wei X, Senanayake TH, Warren G, et al. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjug Chem. 2013;24:658–668.
   PubMed Web of Science ®Google Scholar
• Swaminathan SK, Roger E, Toti U, et al. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release. 2013;171:280–287.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu W-L, Guo J, et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release. 2008;129:18–25.
   PubMed Web of Science ®Google Scholar
• Sadhukha T, Niu L, Wiedmann TS, et al. Effective elimination of cancer stem cells by magnetic hyperthermia. Mol Pharm. 2013;10:1432–1441.
   PubMed Web of Science ®Google Scholar
• Kowalski P, Stein U, Scheffer GL, et al. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther. 2002;9:579–586.
   PubMed Web of Science ®Google Scholar
• Materna V, Liedert B, Thomale J, et al. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer. 2005;115:393–402.
   PubMed Web of Science ®Google Scholar
• Kowalski P, Surowiak P, Lage H. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther. 2005;11:508–522.
   PubMed Web of Science ®Google Scholar
• Shi Z, Liang Y-J, Chen Z-S, et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther. 2006;5:39–47.
   PubMed Web of Science ®Google Scholar
• Tian X, Zamek-Gliszczynski MJ, Zhang P, et al. Modulation of multidrug resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes. Mol Pharmacol. 2004;66:1004–1010.
   PubMed Web of Science ®Google Scholar
• Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther. 2004;3:833–838.
   PubMed Web of Science ®Google Scholar
• Xiao H, Wu Z, Shen H, et al. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi. Basic Clin Pharmacol Toxicol. 2008;103:342–348.
   PubMed Web of Science ®Google Scholar
• Sepp-Lorenzino L, Ruddy M. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin Pharmacol Ther. 2008;84:628–632.
   PubMed Web of Science ®Google Scholar
• Stein U, Walther W, Stege A, et al. Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol Ther. 2008;16:178–186.
   PubMed Web of Science ®Google Scholar
• DeSano JT, Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. Aaps J. 2009;11:682–692.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wu H, Liu X, et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582–588.
   PubMed Web of Science ®Google Scholar
• Turrini E, Haenisch S, Laechelt S, et al. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics. 2012;22:198–205.
   PubMed Web of Science ®Google Scholar
• Liang Z, Wu H, Xia J, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010;79:817–824.
   PubMed Web of Science ®Google Scholar
• Pisco AO, Jackson DA, Huang S. Reduced intracellular drug accumulation in drug-resistant leukemia cells is not only solely due to mdr-mediated efflux but also to decreased uptake. Front Oncol. 2014;4:306.
   PubMedGoogle Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.
   PubMed Web of Science ®Google Scholar
• Oberdorster G, Utell MJ. Ultrafine particles in the urban air: to the respiratory tract–and beyond? Environ Health Perspect. 2002;110:A440–A441.
   PubMed Web of Science ®Google Scholar
• Kreyling WG, Semmler M, Erbe F, et al. Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. J Toxicol Environ Health A. 2002;65:1513–1530.
   PubMed Web of Science ®Google Scholar
• Kroll A, Pillukat MH, Hahn D, et al. Current in vitro methods in nanoparticle risk assessment: limitations and challenges. Eur J Pharm Biopharm. 2009;72:370–377.
   PubMed Web of Science ®Google Scholar
• Stern ST, Adiseshaiah PP, Crist RM. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part Fibre Toxicol. 2012;9:20.
   PubMed Web of Science ®Google Scholar
• Sinha R, Kim GJ, Nie S, et al. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006;5:1909–1917.
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Turpeinen M, Uusitalo J, et al. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin Pharmacol Toxicol. 2005;96:167–175.
   PubMed Web of Science ®Google Scholar
• Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature. 2007;446:749–757.
   PubMed Web of Science ®Google Scholar
• von Manstein V, Yang CM, Richter D, et al. Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr Signal Transduct Ther. 2013;8:193–202.
   PubMed Web of Science ®Google Scholar